Brainstorm Cell Therapeutics, Inc.
BCLI
Market Cap$7.7M
Close$
$2.48
110.5% upside
Current Fair Value
110.5% upsideUndervalued by 110.5% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $7.70 Million |
|---|---|
| Enterprise Value | $8.23 Million |
| Dividend Yield | $0 (0%) |
| Earnings per Share | $2.19 |
| Beta | 0.34 |
| Outstanding Shares | 6,141,762 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | -0.62 |
|---|---|
| PEG | -0.52 |
| Price to Sales | - |
| Price to Book Ratio | -0.59 |
| Enterprise Value to Revenue | 59.2 |
| Enterprise Value to EBIT | -0.62 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 0.09 |
| Debt to Equity | -0.09 |
Revenue Sources
No data
Insider Trades
ESG Score
No data
About Brainstorm Cell Therapeutics, Inc.
CEO: Chaim Lebovits